Lower extremity arterial disease perspective: IUA consensus document on "lead management". Part 1.

IF 1.5 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

International Angiology Pub Date : 2023-10-01 Epub Date: 2023-10-12 DOI:10.23736/S0392-9590.23.05110-6

Pier Luigi Antignani, Mauro Gargiulo, Giacomo Gastaldi, Arkadiusz Jawien, Armando Mansilha, Pavel Poredos

引用次数: 0

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is defined as coronary heart disease (CHD), cerebrovascular disease, or lower extremity arterial disease (LEAD) also named peripheral arterial disease (PAD). ASCVD is considered to be of atherosclerotic origin and is the leading cause of morbidity and mortality mainly for individuals with diabetes mellitus (DM). In this consensus document of the International Union of Angiology the authors discuss epidemiology, risk factors, primary and secondary prophylaxis, the correlation between diabetes mellitus and LEAD, conservative and surgical treatment.

查看原文本刊更多论文

下肢动脉疾病观点：IUA关于“铅管理”的共识文件。第1部分。

动脉粥样硬化性心血管疾病（ASCVD）被定义为冠心病（CHD）、脑血管疾病或下肢动脉疾病（LEAD），也称为外周动脉疾病（PAD）。ASCVD被认为是动脉粥样硬化起源的，是主要导致糖尿病（DM）患者发病率和死亡率的主要原因。在国际血管学联合会的这份共识文件中，作者讨论了流行病学、危险因素、一级和二级预防、糖尿病与LEAD之间的相关性、保守治疗和手术治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Angiology 医学-外周血管病

CiteScore

2.80

自引率

28.60%

发文量

审稿时长

6-12 weeks

期刊介绍： International Angiology publishes scientific papers on angiology. Manuscripts may be submitted in the form of editorials, original articles, review articles, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work. Duties and responsibilities of all the subjects involved in the editorial process are summarized at Publication ethics. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (ICMJE).